OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process
  • Publisher Calendar

  • Products & Pricing
  • Banner Advertising Plans
  • eNewsletter Packages
  • Pre-Roll Advertising
  • Create A Deep Dive Conversation
  • Create a Video Release (VR)
  • Boost Earned Media Only $60

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5597
  • Acute Myelogenous Leukemia 226
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 563
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 209
  • Chronic Myelogenous Leukemia 54
  • Colorectal 172
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 178
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 206
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 179
  • Kidney 393
  • Liver 40
  • Lung 97
  • Lymphoma 236
  • Melanoma and Skin 107
  • Multiple Myeloma 535
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 554
  • Other 518
  • Ovarian 65
  • Pancreatic 104
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Michael Wang, MD @michaelwangmd @MDAndersonNews @KitePharma FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL
0:07:00

Michael Wang, MD @michaelwangmd @MDAndersonNews @KitePhar...

Michael Wang, MD at MD Anderson discusses Kite Pharma's FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL

US. U.S. Food and Drug Administration ( FDA) has granted TecartusTM (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimerical antigen receptor (CAR ) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Following a priority review and FDA Breakthrough Therapy Classification, approval of this one-time therapy is based on the findings of ZUMA-2, a single-arm, open-label trial in which 87 percent of patients responded to a single Tecartus infusion, including 62 percent of patients who obtained a full response (CR). 18 percent experienced Grade 3 or higher cytokine release syndrome (CRS) among patients assessable for protection and 37 percent experienced Grade 3 or higher neurological toxicities.

Multimedia features for this press release. Here is the complete release: https:/www.businesswire.com/news/home/20200724005428/en/en/20200724005428

"There are still substantial treatment disparities for patients with MCL who are improving after initial therapy, despite encouraging advances," said Michael Wang, MD, ZUMA-2 Lead Investigator and Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center. "Most patients suffer from high-risk illness, and are more likely to fail to improve even after subsequent treatment. The availability of Tecartus as the first-ever cell therapy for patients with relapsed / refractory MCL offers a significant alternative, with a response rate of almost 90% and early clinical evidence indicating long-lasting remissions in subsequent treatment lines.

Christi Shaw, Chief Executive Officer of Kite, said, "Kite is committed to bringing the promise of CAR T therapy to patients with hematological cancers and, as such, we are proud to launch our second cell therapy." "I extend my gratitude to Kite 's patient study participants, caregivers, clinical researchers, regulators and devoted colleagues who have helped make this approval possible, and we look forward to working with the lymphoma community to provide patients with relapsed or refractory MCL with this potentially revolutionary treatment."

In its product mark, Tecartus has a Boxed Warning about the dangers of CRS and neurologic toxicities. The FDA has approved a Risk Assessment and Mitigation Strategy (REMS) for Tecartus and combined it with the Yescarta ® (axicabtagene ciloleucel) REMS. The REMS curriculum will advise and educate healthcare practitioners on the risks associated with the treatment of Tecartus, and REMS training and certification will be an important part of the final authorisation for the centers providing Tecartus. You can find more information on the REMS software at www. YescartaTecartusREMS.com. For Essential Safety Details please see below.

MCL is an uncommon type of non-Hodgkin lymphoma (NHL) that occurs from cells that originate in the lymph node's "mantle region" and primarily affects men over the age of 60. Following relapse, MCL is extremely aggressive, with many patients improving following therapy.

Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, said: 'This approval is the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease. "Researchers have made tremendous strides in our understanding of this disease over the past decade and we have seen a rise in patient clinical trials, which we hope will continue to enhance treatment methods and choices for people with mantle cell lymphoma. Today's news builds on this advancement and gives hope that cell patients and their loved ones will be mantled.

Tecartus will be assembled in El Segundo, California, at Kite 's commercial manufacturing facility. Kite showed a 96% manufacturing success rate in the ZUMA-2 trial and a median manufacturing turnaround time of 15 days from leukapheresis to product delivery. Pace of development is highly important for advanced disease patients who are extremely ill and at risk of rapid progression.

Kite Konnect ®, an advanced technology platform that offers information and assistance during the therapy process for Kite's commercialized CAR T therapies, including courier monitoring for shipments and development status updates, will work with patients whose healthcare providers have prescribed Tecartus therapy. Kite Konnect offers assistance to qualifying patients obtaining Yescarta and Tecartus and offers information to assist their patients in the healthcare teams. Patients and healthcare professionals can contact Kite Konnect at www. KiteKonnect.com or 1-844-454-KITE (1-844-454-5483).

KTE-X19 is currently under review in the European Union and has been awarded the European Medicines Agency's Priority Medicines (PRIME) designation for relapsed or refractory MCL.

Tecartus Trial Results
Data from the ongoing, single arm, open-label ZUMA-2 pivotal trial supports the approval of Tecartus. The study enrolled 74 adult patients with relapsed or refractory MCL who had previously undergone chemotherapy containing anthracycline or bendamustine, anti-CD20 antibody therapy and an inhibitor of Bruton tyrosine kinase (ibrutinib or acalabrutinib). The primary endpoint, as assessed by the Independent Radiological Review Committee (IRRC), was the objective response rate (ORR) per Lugano Classification (2014), defined as the combined rate of CR and partial responses.

In the study, 87 percent of patients responded to a single infusion of Tecartus (n=60 evaluable for efficacy analysis), including 62 percent of patients who achieved a CR. The follow-up was at least six months after their first objective disease response, for all patients. The median response period has not yet been achieved.

In the study, 18 percent of patients experienced Grade 3 or higher CRS and 37 percent experienced neurologic incidents (n=82 assessable for safety). Anemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatremia, hypertension, infection-pathogen not defined, pneumonia, hypocalcemia and lymphopenia were the most common (approximately 10%) Grade 3 or higher adverse reactions. With a Risk Assessment and Mitigation Plan (REMS), the FDA approved Tecartus. The Tecartus REMS is now called the "Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) REMS Program" (www. YescartaTecartusREMS.com) in conjunction with the Yescarta REMS program.

179 Views
2 years Ago
AACR
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Non-Hodgkin Lymphoma

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
0:05:13
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
19 Views
2 months Ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
143 Views
2 months Ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
0:06:08
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
185 Views
2 months Ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Alexey Danilov, MD @cityofhope #AACR21 #NonHodgkinLymphoma #Cancer #Research Pharmacologic targeting Mcl-1 with AZD5991 induces apoptosis, suppresses mitochondrial respiration and overcom...
0:06:47
Alexey Danilov, MD @cityofhope #AACR21 #NonHodgkinLymphom...
437 Views
1 year Ago
AACR
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Danelle James, M.D. @Pharmacyclics #WalenstromsMacroglobulinemia #Non-HodgkinsLymphoma #iNNOVATE #Cancer #Research Ibrutinib U.S. Prescribing Information Updated to Include Long-Term Data...
00:09:15
Danelle James, M.D. @Pharmacyclics #WalenstromsMacroglobu...
93 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mazyar Shadman, M.D., M.P.H.@mshadman @fredhutch #Non-HodgkinLymphoma #Cancer #Research Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy
00:11:34
Mazyar Shadman, M.D., M.P.H.@mshadman @fredhutch #Non-Hod...
81 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Rajat Bannerji, MD, Ph.D. @RutgersCancer #ASH20 #NonHodgkinLymphoma #Cancer #Research 400 Odronextamab (REGN1979)
00:19:13
Rajat Bannerji, MD, Ph.D. @RutgersCancer #ASH20 #NonHodgk...
57 Views
2 years Ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Michael Wang, MD @michaelwangmd @MDAndersonNews @KitePharma FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL
0:07:00
Michael Wang, MD @michaelwangmd @MDAndersonNews @KitePhar...
179 Views
2 years Ago
AACR
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Caron Jacobson, MD on Interim Analysis of ZUMA-5 #ASCO2020 @DanaFarber
0:05:32
Caron Jacobson, MD on Interim Analysis of ZUMA-5 #ASCO202...
17 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
John Kuruvilla, MD on A New Standard in Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO
0:02:15
John Kuruvilla, MD on A New Standard in Phase II Study of...
17 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
John Kuruvilla, MD on the Specific of the Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO
0:02:51
John Kuruvilla, MD on the Specific of the Phase II Study ...
49 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
John Kuruvilla, MD on KEYNOTE-204: Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO
0:01:27
John Kuruvilla, MD on KEYNOTE-204: Phase II Study of Pemb...
40 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - (951) 326-8827